Vnfin, please explain why you think Pharmasset is including ribavirin in all their upcoming all-oral trials directed against genotypes 1,2 and 3. Why not just go with monotherapy using PSI-7977 if it is potent enough to do the job against all three genotypes? That would certainly be more impressive. Why does it "appease the FDA", as you put it, to include ribavirin in their trials? Apparently, what you are saying is that Vertex needs ribavirin to improve their chance of success in all-oral hep C regimens but Pharmasset needs ribavirin to appease the FDA.